| Autor: |
Stern, Andrew M., Van Pelt, Kathryn L., Liu, Lei, Anderson, Amirah K., Ostaszewski, Beth, Mapstone, Mark, O’Bryant, Sid, Petersen, Melissa E., Christian, Bradley T., Handen, Benjamin L., Selkoe, Dennis J., Schmitt, Frederick, Head, Elizabeth |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
medRxiv |
| Popis: |
INTRODUCTION: People with Down syndrome (DS) often develop Alzheimer disease (AD). Here we asked whether ultrasensitive plasma immunoassays for a tau N-terminal fragment (NT1-tau) and Aβ isoforms predict cognitive impairment. METHODS: Plasma NT1-tau, Aβ (37) , Aβ (40) , and Aβ (42) levels were measured in a longitudinal discovery cohort (N = 85 participants, 220 samples) and a cross-sectional validation cohort (N = 239). We developed linear models and predicted values in the validation cohort. RESULTS: Linear mixed models for NT1-tau, Aβ (42,) and Aβ (37:42) were significant for age, there was no main effect of time in the discovery cohort. In cross-sectional models, NT1-tau and Aβ (42) increased with age. NT1-tau predicted DLD scores. The discovery cohort linear model for NT1-tau predicted NT1-tau levels in the validation cohort. DISCUSSION: NT1-tau correlates with age and worse cognition in DS. Further validation of NT1-tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
